Teva Upbeat On Partnered Biosimilars With EU Ranibizumab Set For 2022

‘We Are Addressing Some 80% Of The Value Going Off-Patent In The Coming Years’

 
• By Dean Rudge
  
EU flag Europe thumbs up
Teva expects to launch partner Bioeq's ranibizumab in 2022 • Source: YAY Media AS / Alamy Stock Photo

More from Biosimilars

More from Products